AG˹ٷ

STOCK TITAN

[8-K] Cumberland Pharmaceuticals Inc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Credo Technology Group (CRDO) � Form 4 insider transaction: Chi Fung Cheng, the company’s Chief Technology Officer and director, disclosed the sale of 55,000 ordinary shares on 01-Aug-2025 under a Rule 10b5-1 trading plan adopted 06-Sep-2024.

  • Seven separate trades were executed at weighted-average prices ranging $103.64�$109.55 per share.
  • Approximate gross proceeds: about US$5.9 million (derived from share/price data disclosed).
  • Post-sale, Cheng (via the Cheng Huang Family Trust) still beneficially owns 7,108,961 ordinary shares, indicating the disposition represents �0.8 % of his indirect holdings.

No derivative transactions were reported. The filing appears routine and does not indicate any change in corporate strategy or fundamentals.

Credo Technology Group (CRDO) � Transazione interna Form 4: Chi Fung Cheng, Chief Technology Officer e direttore della società, ha comunicato la vendita di 55.000 azioni ordinarie il 01-agosto-2025 nell'ambito di un piano di trading Rule 10b5-1 adottato il 06-settembre-2024.

  • Sono state eseguite sette operazioni separate con prezzi medi ponderati compresi tra $103,64 e $109,55 per azione.
  • Proventi lordi approssimativi: circa 5,9 milioni di dollari USA (calcolati dai dati di azioni/prezzo comunicati).
  • Dopo la vendita, Cheng (tramite il Cheng Huang Family Trust) detiene ancora beneficiariamente 7.108.961 azioni ordinarie, indicando che la cessione rappresenta circa lo 0,8% delle sue partecipazioni indirette.

Non sono state segnalate transazioni derivati. La comunicazione appare di routine e non indica cambiamenti nella strategia aziendale o nei fondamentali.

Credo Technology Group (CRDO) � Transacción interna Formulario 4: Chi Fung Cheng, Director de Tecnología y director de la empresa, reveló la venta de 55,000 acciones ordinarias el 01 de agosto de 2025 bajo un plan de negociación Rule 10b5-1 adoptado el 06 de septiembre de 2024.

  • Se ejecutaron siete operaciones separadas con precios promedio ponderados entre $103.64 y $109.55 por acción.
  • Ingresos brutos aproximados: alrededor de 5.9 millones de dólares estadounidenses (derivado de los datos de acciones/precio divulgados).
  • Después de la venta, Cheng (a través del Cheng Huang Family Trust) aún posee beneficiariamente 7,108,961 acciones ordinarias, lo que indica que la disposición representa aproximadamente el 0.8% de sus tenencias indirectas.

No se reportaron transacciones con derivados. La presentación parece rutinaria y no indica ningún cambio en la estrategia corporativa o en los fundamentos.

Credo Technology Group (CRDO) � Form 4 내부� 거래 보고: 회사� 최고기술책임�(CTO) � 이사� Chi Fung Cheng가 2025� 8� 1일에 2024� 9� 6� 채택� Rule 10b5-1 거래 계획� 따라 55,000� 보통� 매도� 공시했습니다.

  • 7건의 별도 거래가 주당 $103.64~$109.55� 가중평� 가격으� 실행되었습니�.
  • 대략적� � 수익: 공시� 주식/가� 데이터를 기준으로 � 590� 미국 달러입니�.
  • 매도 � Cheng� (Cheng Huang 가� 신탁� 통해) 여전� 7,108,961� 보통�� 실질적으� 보유하고 있으�, 이는 그의 간접 보유 지분의 � 0.8%� 해당합니�.

파생상품 거래� 보고되지 않았습니�. 이번 공시� 일상적인 것으� 보이� 회사 전략이나 기본 사항� 변화를 나타내지 않습니다.

Credo Technology Group (CRDO) � Transaction d’initié Formulaire 4 : Chi Fung Cheng, directeur technique et administrateur de la société, a déclaré la vente de 55 000 actions ordinaires le 1er août 2025 dans le cadre d’un plan de trading Rule 10b5-1 adopté le 6 septembre 2024.

  • Sept transactions distinctes ont été exécutées à des prix moyens pondérés allant de 103,64 $ à 109,55 $ par action.
  • Produit brut approximatif : environ 5,9 millions de dollars américains (calculé à partir des données d’actions/prix divulguées).
  • Après la vente, Cheng (via le Cheng Huang Family Trust) détient toujours bénéficiairement 7 108 961 actions ordinaires, ce qui indique que la cession représente environ 0,8 % de ses participations indirectes.

Aucune transaction sur dérivés n’a été signalée. Le dépôt semble routinier et n’indique aucun changement dans la stratégie d’entreprise ou les fondamentaux.

Credo Technology Group (CRDO) � Insider-Transaktion Form 4: Chi Fung Cheng, Chief Technology Officer und Direktor des Unternehmens, meldete am 01. August 2025 den Verkauf von 55.000 Stammaktien im Rahmen eines Rule 10b5-1 Handelsplans, der am 06. September 2024 angenommen wurde.

  • Es wurden sieben separate Transaktionen zu gewichteten Durchschnittspreisen zwischen pro Aktie ausgeführt.
  • Ungefähre Bruttoerlöse: ca. 5,9 Millionen US-Dollar (abgeleitet aus den offengelegten Aktien-/Preisdaten).
  • Nach dem Verkauf besitzt Cheng (über den Cheng Huang Family Trust) weiterhin wirtschaftlich 7.108.961 Stammaktien, was darauf hindeutet, dass die Veräußerung etwa 0,8 % seiner indirekten Beteiligungen ausmacht.

Es wurden keine Derivatgeschäfte gemeldet. Die Meldung erscheint routinemäßig und deutet nicht auf eine Änderung der Unternehmensstrategie oder der Fundamentaldaten hin.

Positive
  • Sale executed under a disclosed Rule 10b5-1 plan, signalling pre-arranged, non-opportunistic intent.
  • Insider retains a substantial 7.1 million-share position, implying continued alignment with shareholders.
Negative
  • 55,000 shares sold for roughly US$5.9 million could be perceived as profit-taking.
  • All reported transactions were sales; no offsetting purchases to indicate increasing insider conviction.

Insights

TL;DR: Routine 55 k-share 10b5-1 sale; negligible vs. 7.1 m stake, limited market signal.

The CTO’s 55,000-share sale (~US$5.9 m) is <1 % of his indirect ownership and was executed under a pre-established 10b5-1 plan, reducing concerns about opportunistic selling. While insider sales can pressure sentiment, the small percentage and continued large holding (7.1 m shares) suggest confidence remains. Impact on valuation or fundamentals is minimal; I view the disclosure as neutral for investors.

Credo Technology Group (CRDO) � Transazione interna Form 4: Chi Fung Cheng, Chief Technology Officer e direttore della società, ha comunicato la vendita di 55.000 azioni ordinarie il 01-agosto-2025 nell'ambito di un piano di trading Rule 10b5-1 adottato il 06-settembre-2024.

  • Sono state eseguite sette operazioni separate con prezzi medi ponderati compresi tra $103,64 e $109,55 per azione.
  • Proventi lordi approssimativi: circa 5,9 milioni di dollari USA (calcolati dai dati di azioni/prezzo comunicati).
  • Dopo la vendita, Cheng (tramite il Cheng Huang Family Trust) detiene ancora beneficiariamente 7.108.961 azioni ordinarie, indicando che la cessione rappresenta circa lo 0,8% delle sue partecipazioni indirette.

Non sono state segnalate transazioni derivati. La comunicazione appare di routine e non indica cambiamenti nella strategia aziendale o nei fondamentali.

Credo Technology Group (CRDO) � Transacción interna Formulario 4: Chi Fung Cheng, Director de Tecnología y director de la empresa, reveló la venta de 55,000 acciones ordinarias el 01 de agosto de 2025 bajo un plan de negociación Rule 10b5-1 adoptado el 06 de septiembre de 2024.

  • Se ejecutaron siete operaciones separadas con precios promedio ponderados entre $103.64 y $109.55 por acción.
  • Ingresos brutos aproximados: alrededor de 5.9 millones de dólares estadounidenses (derivado de los datos de acciones/precio divulgados).
  • Después de la venta, Cheng (a través del Cheng Huang Family Trust) aún posee beneficiariamente 7,108,961 acciones ordinarias, lo que indica que la disposición representa aproximadamente el 0.8% de sus tenencias indirectas.

No se reportaron transacciones con derivados. La presentación parece rutinaria y no indica ningún cambio en la estrategia corporativa o en los fundamentos.

Credo Technology Group (CRDO) � Form 4 내부� 거래 보고: 회사� 최고기술책임�(CTO) � 이사� Chi Fung Cheng가 2025� 8� 1일에 2024� 9� 6� 채택� Rule 10b5-1 거래 계획� 따라 55,000� 보통� 매도� 공시했습니다.

  • 7건의 별도 거래가 주당 $103.64~$109.55� 가중평� 가격으� 실행되었습니�.
  • 대략적� � 수익: 공시� 주식/가� 데이터를 기준으로 � 590� 미국 달러입니�.
  • 매도 � Cheng� (Cheng Huang 가� 신탁� 통해) 여전� 7,108,961� 보통�� 실질적으� 보유하고 있으�, 이는 그의 간접 보유 지분의 � 0.8%� 해당합니�.

파생상품 거래� 보고되지 않았습니�. 이번 공시� 일상적인 것으� 보이� 회사 전략이나 기본 사항� 변화를 나타내지 않습니다.

Credo Technology Group (CRDO) � Transaction d’initié Formulaire 4 : Chi Fung Cheng, directeur technique et administrateur de la société, a déclaré la vente de 55 000 actions ordinaires le 1er août 2025 dans le cadre d’un plan de trading Rule 10b5-1 adopté le 6 septembre 2024.

  • Sept transactions distinctes ont été exécutées à des prix moyens pondérés allant de 103,64 $ à 109,55 $ par action.
  • Produit brut approximatif : environ 5,9 millions de dollars américains (calculé à partir des données d’actions/prix divulguées).
  • Après la vente, Cheng (via le Cheng Huang Family Trust) détient toujours bénéficiairement 7 108 961 actions ordinaires, ce qui indique que la cession représente environ 0,8 % de ses participations indirectes.

Aucune transaction sur dérivés n’a été signalée. Le dépôt semble routinier et n’indique aucun changement dans la stratégie d’entreprise ou les fondamentaux.

Credo Technology Group (CRDO) � Insider-Transaktion Form 4: Chi Fung Cheng, Chief Technology Officer und Direktor des Unternehmens, meldete am 01. August 2025 den Verkauf von 55.000 Stammaktien im Rahmen eines Rule 10b5-1 Handelsplans, der am 06. September 2024 angenommen wurde.

  • Es wurden sieben separate Transaktionen zu gewichteten Durchschnittspreisen zwischen pro Aktie ausgeführt.
  • Ungefähre Bruttoerlöse: ca. 5,9 Millionen US-Dollar (abgeleitet aus den offengelegten Aktien-/Preisdaten).
  • Nach dem Verkauf besitzt Cheng (über den Cheng Huang Family Trust) weiterhin wirtschaftlich 7.108.961 Stammaktien, was darauf hindeutet, dass die Veräußerung etwa 0,8 % seiner indirekten Beteiligungen ausmacht.

Es wurden keine Derivatgeschäfte gemeldet. Die Meldung erscheint routinemäßig und deutet nicht auf eine Änderung der Unternehmensstrategie oder der Fundamentaldaten hin.

0001087294false00010872942025-08-052025-08-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

August 5, 2025 (August 5, 2025)
Date of Report (date of earliest event reported)

CUMBERLAND PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
Tennessee
001-33637
62-1765329
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
1600 West End Avenue, Suite 1300 Nashville, Tennessee 37203
(Address of Principal Executive Offices)
(615) 255-0068
Registrant's telephone number, including area code


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, no par valueCPIXNASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02     Results of Operations and Financial Condition.

On August 5, 2025, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three and six months ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.
This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by Item 2.02.
Item 9.01    Financial Statements and Exhibits
    (d) Exhibits
   
Exhibit No. Description
 
99.1
 
Press release dated August 5, 2025



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  Cumberland Pharmaceuticals Inc.
Dated: August 5, 2025
  By:/s/ John Hamm
  John Hamm
  Chief Financial Officer

FAQ

How many Credo (CRDO) shares did the CTO sell?

The filing shows 55,000 ordinary shares were sold on 01-Aug-2025.

At what prices were the CRDO shares sold?

Weighted-average sale prices ranged from $103.64 to $109.55 per share across seven trades.

Was the sale pre-planned?

Yes. The sales were executed under a Rule 10b5-1 trading plan adopted on 06-Sep-2024.

How many CRDO shares does the insider still own?

Post-transaction, the Cheng Huang Family Trust holds 7,108,961 ordinary shares.

Does this insider sale materially affect Credo’s outlook?

The sale represents �0.8 % of the insider’s stake and is considered routine, with no stated impact on company operations or guidance.
Cumberland Pharmaceuticals Inc

NASDAQ:CPIX

CPIX Rankings

CPIX Latest News

CPIX Latest SEC Filings

CPIX Stock Data

52.66M
8.74M
41.55%
28.76%
0.04%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
NASHVILLE,